AbbVie Downplays Impact Of Viekira Pak Safety Issues
This article was originally published in Scrip
Executive Summary
AbbVie Inc. continued to downplay the potential impact of a labeling change for its hepatitis C combination drug Viekira Pak, saying during its third quarter earnings call on Oct. 30 that the safety-driven update affects a small percentage of patients and won't prove material to the product's sales.
You may also be interested in...
AbbVie Might Be Most Affected By FDA’s HCV Drug Safety Warning
A US FDA warning of serious liver injuries in hepatitis C patients treated with combo pills from AbbVie, Gilead and Merck may impact AbbVie's Mavyret most, since it's one of the company's top sellers.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.